Clinical Trial Update: Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types [Phase 2]

View source ↗

Summary

Phase II clinical trial of Brivanib (BMS-582664) across multiple tumor types has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Soft Tissue Sarcoma
• Transitional Cell Carcinoma

Drugs mentioned

• Brivanib (brivanib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma | Phase 2 | Status: COMPLETED